Acrux announces commercial agreement with Padagis
Filed with ASX · · 2 pages · English
Melbourne, Australia; 20 June 2022: Acrux Limited (ASX:ACR) is pleased to announce that it has entered into an exclusive commercialisation agreement with Padagis in the United States for one of the products in the Acrux portfolio. Padagis is a leading US-based provider of extended topical and other specialty pharmaceutical products with over two hundred products on the market today. Formerly the R
Earlier from Acrux
- Successful patent litigation outcome
- Appendix 4D, Half Year Accounts as at 31 December 2021
- Acrux and Harris terminate license agreement
- Acruxs fifth generic dossier accepted by FDA for review
- Acrux Investor Presentation - September 2021
Later from Acrux
- Acruxs sixth generic dossier accepted by FDA for review
- Appendix 4E and FY22 Annual Report
- Remaining balance of R&D Tax Incentive Rebate received
- Chairman and CEO address to AGM
- Mutual Termination of Co-Development Agreement
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux